Reglan and Tardive Dyskinesia: What Arizona Patients Should Know
From General Health Information to Occupational Exposure Concerns
If you or a loved one developed uncontrollable facial or limb movements after taking Reglan (metoclopramide), you may be facing tardive dyskinesia. Decades of pharmacovigilance and neurological research have established this risk, particularly with long-term use. This page outlines the clinical timeline, FDA warnings, and key discussion points for Arizona patients.
Reglan and Tardive Dyskinesia: Medical Evidence and Risks
Reglan (metoclopramide) is a medication approved for short-term treatment of symptomatic gastroesophageal reflux in adults and for relief of symptoms in adults with acute and recurrent diabetic gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The drug carries a boxed warning stating that metoclopramide, including Reglan, can cause tardive dyskinesia (TD), a potentially irreversible serious movement disorder (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The risk of developing TD increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is contraindicated in patients with a history of TD, and the prescribing information instructs clinicians to use the drug for the shortest duration necessary and to periodically reassess the need for continued treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with symptomatic, documented gastroesophageal reflux, the maximum duration of Reglan treatment is 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). In patients with diabetic gastroparesis, total treatment duration should not exceed 12 weeks; if longer-term use is unavoidable, routine monitoring for signs and symptoms of TD is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Tardive dyskinesia is characterized by potentially irreversible and disfiguring involuntary movements of the face or tongue, and sometimes of the trunk and/or extremities (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Metoclopramide may also suppress or partially suppress the signs of TD, potentially delaying diagnosis because it can mask the underlying disease process (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The drug is not recommended for use in pediatric patients due to the risk of TD and other extrapyramidal symptoms, as well as the risk of methemoglobinemia in neonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
Statute of Limitations for Reglan Lawsuits in Arizona
For patients in Arizona who have developed TD after taking Reglan, the statute of limitations is a critical legal consideration. The statute of limitations sets a time limit on when a lawsuit can be filed. In Arizona, personal injury claims generally must be filed within two years from the date the injury is discovered or reasonably should have been discovered. For TD, the timeline between exposure to Reglan and the onset of symptoms can be variable, often occurring after months or years of use. The boxed warning emphasizes that the risk increases with longer treatment duration and higher cumulative doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This delayed onset can complicate the determination of when the statute of limitations begins to run. Patients may not immediately recognize the involuntary movements as drug-induced, and the diagnosis may be made only after a neurological evaluation. Settlement-related considerations for affected patients include the adequacy of warnings provided by the manufacturer. The boxed warning on Reglan clearly states the risk of TD and the need for short-term use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, some patients may have been prescribed Reglan for longer than the recommended 12-week period, or without adequate monitoring. The warning also advises immediate discontinuation of Reglan if signs or symptoms of TD develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). In settlement contexts, the strength of a claim may depend on whether the prescribing physician followed these guidelines and whether the patient was informed of the risks. The mechanistic pathway linking Reglan to TD involves dopamine receptor blockade in the brain, which can lead to supersensitivity and abnormal involuntary movements. The boxed warning notes that metoclopramide can cause TD and that the risk increases with cumulative exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This pharmacological action is well-documented and forms the basis for the warning. For patients considering legal action in Arizona, it is important to document the timeline of Reglan use, the onset of TD symptoms, and the date of diagnosis. Medical records should include the prescribing history, any warnings given, and the clinical presentation of TD. The statute of limitations may be affected by the date of discovery, so prompt consultation with a legal professional is advisable. Settlement amounts can vary based on the severity of TD, the duration of Reglan use, and the degree of warning provided. In summary, Reglan carries a clear boxed warning about the risk of TD, and the drug is indicated only for short-term use. Patients in Arizona who developed TD after prolonged use may have legal recourse, but the statute of limitations requires timely action. The evidence underscores the importance of adhering to prescribing guidelines and monitoring for adverse effects.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the statute of limitations for Reglan lawsuits in Arizona?
In Arizona, personal injury claims generally must be filed within two years from the date the injury is discovered or reasonably should have been discovered. For tardive dyskinesia caused by Reglan, the clock may start when the patient becomes aware of the link between the drug and their symptoms. It is crucial to consult an attorney promptly to avoid missing the deadline.
Can I file a lawsuit if I developed tardive dyskinesia after taking Reglan for more than 12 weeks?
Yes, if you were prescribed Reglan for longer than the recommended 12-week maximum, you may have a claim. The boxed warning emphasizes short-term use, and prolonged use increases the risk of TD. However, the strength of your case depends on whether the prescribing physician followed guidelines and whether you were adequately warned of the risks.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
Related Articles
References
Request a Free Case Review
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.